Impact of computerized dosing on eptifibatide-associated bleeding and mortality

American Heart Journal

Volumn 158, Issue 6, 2009, Pages 1018-1023

  Putney, David R ^a   Kleiman, Neal S ^a   Fromm Jr , Robert E ^a   Buergler, John M ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EPTIFIBATIDE;

ADULT; ALGORITHM; ARTICLE; AUTOMATION; BLEEDING; CATHETERIZATION; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE CLASSIFICATION; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME;

ALGORITHMS; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES;

EID: 70549106492     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.10.006     Document Type: Article

References (23)

1. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
2. Salim Y., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. The Fifth Organization to Assess Strategies in Acute Ischemic Syndrome Investigators (OASIS-5). N Eng J Med 354 (2006) 1464-1476
3. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during Primary PCI in acute myocardial infarction. HORIZONS-AMI Trial Investigators. N Eng J Med 358 (2008) 2118-2130
4. Chew D.P., Lincoff A.M., Gurm H., et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitors with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE 2 Trial). Am J Cardiol 95 (2005) 581-585
5. Eptifibatide [package insert]. Millennium Pharmaceuticals, Inc and Schering Corporation; 2003.
6. Eptifibatide [package insert]. Millennium Pharmaceuticals, Inc and Schering Corporation; 2006.
7. Alexander K.P., Chen A.Y., Newby L.K., et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors. Results from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative. Circulation 114 (2006) 1380-1387
8. Rasty S., Borzak S., and Tisdale J.E. Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors. J Clin Pharmacol 42 (2002) 1366-1373
9. Kirtane A.J., Piazza G., Murphy S.A., et al. Correlates of bleeding events among moderate-to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide. Observations from the PROTECT-TIMI-30 Trial. J Am Coll Cardiol 47 (2006) 2374-2379
10. Robert S., Zarowitz B.J., Peterson E.L., et al. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med 21 (1993) 1487-1495
11. Stevens L.A., Nolin T.D., and Richardson M.M. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 54 (2009) 33-42
12. Rao S.V., O'Grady K., and Pieper K.S. A Comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. JACC 47 (2006) 809-816
13. Tcheng, et al. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 356 (2000) 2037-2044
14. Harrington R.A. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Eng J Med 339 (1998) 436-443
15. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 289 (2003) 853-863
16. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 2 Suppl 1 (2002) S1-S266
17. Rhodes P.J., Rhodes R.S., McClelland G.H., et al. Evaluation of eight methods for estimating creatinine clearance in men. Clin Pharm 6 (1997) 399-406
18. Rosborough T.K., Shepherd M.F., and Couch P.L. Selecting an equation to estimate glomerular filtration rate for use in renal dosage adjustment of drugs in electronic patient record systems. Pharmacotherapy 25 (2005) 823-830
19. Shoker A., Hossain M.A., Koru-Sengul T., et al. Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol 66 (2006) 89-97
20. Marx G.M., Blake G.M., Galani E., et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15 (2004) 291-295
21. O'Connell M.B., Dwinell A.M., and Bannick-Mohrland S.D. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 26 (1992) 627-635
22. Davis G.A., and Chandler M.H. Comparison of creatinine clearance estimation methods in patients with trauma. Am J Health Syst Pharm 53 (1996) 1028-1032
23. Stone W.S., McLaurin B.T., and Cox D.A. Bivalirudin for patients with acute coronary syndromes. The ACUITY Investigators. N Eng J Med 355 (2006) 2203-2216